Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract that is now spreading to several countries in the world, including Brazil. Mortality rates after infection are higher in adults over 60 and with a history of comorbidities. The most serious patients need care in intensive care units (ICU). Most of the time they depend on mechanical ventilation support due to acute respiratory distress syndrome (ARDS). Infection rates are higher than the capacity for intensive care, which represents a serious problem in medical care. Around 20% of those infected have severe pneumonia and so far it does not have a specific therapy, or even, an effective clinical management. Therapeutic options using malaria drugs chloroquine and hydroxychloroquine have shown promising results in vitro and in vivo test. A recent, small, non-randomized study with hydroxychloroquine in 36 patients infected with SARS-Cov-2 proved to be promising in the ability to reset the viral load in 6 days after starting treatment. Thus, the present study will evaluate the effectiveness and safety of the use of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in the clinical evolution by the ordinal scale of 6 points in adult patients hospitalized with pneumonia caused by infection by the SARS-CoV2 virus in Brazil.

Inclusion criteria

• Males and females aged > 18 years;
• Suspected or confirmed infection by SARS-CoV2;

Presenting with one of the following:

• Need for oxygen supplementation > 4 L/min, or
• Need for high-flow nasal canula, or
• Need for non-invasive ventilation, or
• Need for mechanical ventilation.

Exclusion criteria

• Refusal to provide written informed consent (either the patient or a legal representative);
• Hypersensitivity to any of the drugs used in the study (Azithromycin or Hydroxychloroquine);
• Patients with more than 48 hours of prior study medication use;
• Patients with onset of symptoms longer than 14 days;
• Patients with long QT syndrome or severe ventricular arrhythmias, not protected by an implantable cardioverter defibrillators (ICD).;
• QTc>= 480ms;
• Do not resuscitate order or exclusive palliative care;
• Patients with liver disease or cirrhosis or abnormal liver enzyme tests above three times the upper limit values (alanine aminotransferase -ALT and aspartate aminotransferase - AST);
• Patients with known retinopathy or macular degeneration;
• Patients with history of pancreatitis;
• Patients with concomitant use of medications that alter the absorption or excretion of azithromycin or hydroxychloroquine;
• Breastfeeding women;
• Pregnancy